Breaking News Instant updates and real-time market news.

CRIS

Curis

$1.23

-0.12 (-8.89%)

, BMY

Bristol-Myers

$60.86

-1.13 (-1.82%)

04:55
11/12/17
11/12
04:55
11/12/17
04:55

Society for Immunotherapy of Cancer to hold annual meeting

32nd Annual Meeting of SITC will be held in National Harbor, MD on November 8-12.

CRIS

Curis

$1.23

-0.12 (-8.89%)

BMY

Bristol-Myers

$60.86

-1.13 (-1.82%)

CLLS

Cellectis

$25.06

-0.58 (-2.26%)

CRSP

Crispr Therapeutics

$17.45

0.5 (2.95%)

JNCE

Jounce Therapeutics

$14.77

0.24 (1.65%)

NKTR

Nektar

$32.50

0.76 (2.39%)

SNDX

Syndax

$10.11

0.09 (0.90%)

IDRA

Idera Pharmaceuticals

$2.11

0.09 (4.46%)

FPRX

Five Prime

$28.83

1.06 (3.82%)

NVS

Novartis

$82.38

-0.1 (-0.12%)

OMED

OncoMed

$4.87

0.14 (2.96%)

DNA

Bought by RHHBY

BAYRY

Bayer

$32.05

-0.211 (-0.65%)

AZN

AstraZeneca

$32.91

-0.2 (-0.60%)

ARRY

Array BioPharma

$11.00

0.18 (1.66%)

TSRO

Tesaro

$91.09

0.08 (0.09%)

XNCR

Xencor

$21.03

1.07 (5.36%)

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 16

    Nov

  • 28

    Nov

  • 29

    Nov

  • 30

    Nov

  • 04

    Dec

  • 06

    Dec

  • 09

    Dec

  • 14

    Dec

  • 05

    Mar

  • 17

    May

  • 30

    Jun

  • 30

    Jun

CRIS Curis
$1.23

-0.12 (-8.89%)

10/23/17
GUGG
10/23/17
INITIATION
Target $7
GUGG
Buy
Curis initiated with a Buy at Guggenheim
Guggenheim analyst Adnan Butt initiated Curis with a Buy and $7 price target.
10/02/17
RHCO
10/02/17
NO CHANGE
RHCO
Curis stock likely to rally 25% on data, says SunTrust
SunTrust analyst Peter Lawson believes there is a 70% chance that data on Curis' oral PD-L1 inhibitor CA-170 in solid tumors will include partial remissions. The analyst estimates that the stock will jump 25% if patients taking the drug have partial remissions, while the stock will fall 10% if there are no partial remissions. The analyst keeps a $3.50 price target and a Buy rating on the shares.
BMY Bristol-Myers
$60.86

-1.13 (-1.82%)

10/30/17
RHCO
10/30/17
UPGRADE
Target $75
RHCO
Buy
Bristol-Myers to benefit from Merck's KN-189 data delay, says SunTrust
As reported earlier, SunTrust analyst John Boris upgraded Bristol-Myers (BMY) to Buy from Hold and raised his price target to $75 from $55, saying Merck's (MRK) KN-189 data delay to 2019 and withdrawal of its EU 1L NSCLC filing improves the company's competitive position. Boris models an additional $2B in 2021 revenue as a result, adding that he has increased confidence in the Opdivo + Yervoy arm of CM-227 trial expected in 2018 to generate overall survival benefits.
11/03/17
STFL
11/03/17
NO CHANGE
Target $25
STFL
Buy
NewLink Genetics price target lowered to $25 from $29 at Stifel
Stifel analyst Stephen Willey trimmed his price target on NewLink Genetics (NLNK) to $25 from $29 to reflect incremental dilution from its recent equity fundraising and forecast for increased operating expenses given that the company will soon initiate its pivotal Phase 3 melanoma trial. The analyst, who expects NewLink shares to remain sensitive to near-term data points on the IDO inhibitor front from Bristol-Myers (BMY) and the partnership of Incyte (INCY) and Merck (MRK), keeps a Buy rating on NewLink shares.
11/08/17
LEER
11/08/17
NO CHANGE
LEER
Outperform
Leerink sees Five Prime recovering some of yesterday's losses
After hosting an investor call to obtain additional information on the efficacy and safety profile of cabiralizumab in pancreatic cancer, Leerink analyst Michael Schmidt expects shares Five Prime Therapeutics (FPRX) will recover some of the losses from yesterday. The efficacy observed in yesterday's data look "quite promising," while safety looks very similar to what has been seen in Opdivo monotherapy trials historically, Schmidt tells investors in a research note. He notes that Five Prime partner Bristol-Myers (BMY) remains highly engaged in the cabiralizumab program. The analyst maintains an Outperform rating on Five Prime shares. The stock in midday trading is up 15%, or $3.85, to $29.71.
10/30/17
10/30/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Intel (INTC) upgraded to Outperform from Market Perform at BMO Capital with analyst Ambrish Srivastava saying the company is starting to execute on delivering operating leverage and also show discipline in its operating model. 2. Conagra Brands (CAG) upgraded to Buy from Hold at Stifel with analyst Christopher Growe citing the stock's valuation, the company's operating profit growth and its optionality to do "aggressive" share repurchase and M&A. 3. Praxair (PX) upgraded to Buy from Neutral at Citi with analyst P.J. Juvekar citing the company's accelerating growth. 4. Bristol-Myers (BMY) upgraded to Buy from Hold at SunTrust with analyst John Boris saying Merck's (MRK) KN-189 data delay to 2019 and withdrawal of its EU 1L NSCLC filing improves the company's competitive position. 5. Curtiss-Wright (CW) upgraded to Buy from Neutral at BofA/Merrill with analyst Kristine Liwag saying it is a significant beneficiary of US Navy submarines and embedded computing. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CLLS Cellectis
$25.06

-0.58 (-2.26%)

09/05/17
FBCO
09/05/17
NO CHANGE
FBCO
Outperform
No read through to Gilead, Kite from Cellectis clinical hold, says Credit Suisse
Credit Suisse analyst Alethia Young said the safety issues that Cellectis (CLLS) is encountering, and which prompted a clinical hold be placed on the company's allogenic CAR-T drug, UCART123, could be to some degree related to the company's platform. She adds that CRS, which led to a death in Cellectis' BPDCN study, is a known issue with CAR-T technologies and cases have been seen in Juno (JUNO) and Kite's (KITE) programs as well. The analyst, who doesn't think there is a read through to Kite and Gilead (GILD) from the Cellectis news and remains confident Kite will receive approval later this fall and launch Axi-Cel, keeps an Outpeform rating on Gilead shares.
09/05/17
JEFF
09/05/17
NO CHANGE
Target $47
JEFF
Buy
Jefferies notes UCART123 not included in Cellectis valuation
After the FDA placed clinical holds on both of its trials, Jefferies analyst Biren Amin notes that UCART123 is not in his valuation for Cellectis. The analyst has a Buy rating on the shares with a $47 price target. The company may need to reevaluate the timing of steroid administration and be more aggressive in treating cytokine release syndrome, Amin tells investors in a research note. He's looking for more information and data on the situation.
09/06/17
RHCO
09/06/17
DOWNGRADE
RHCO
Hold
Cellectis downgraded on patient death, study halt at SunTrust
As noted earlier, SunTrust downgraded Cellectis to Hold from Buy. Analyst Peter Lawson downgraded the stock after a patient died during the company's BPDCN study, leading the FDA to place a clinical hold on both Phase 1 studies of Cellectis' UCART123, a CAR-T drug. Target to $20 from $35.
09/05/17
RHCO
09/05/17
DOWNGRADE
RHCO
Hold
Cellectis downgraded to Hold from Buy at SunTrust
CRSP Crispr Therapeutics
$17.45

0.5 (2.95%)

07/13/17
RHCO
07/13/17
INITIATION
Target $16
RHCO
Hold
CRISPR Therapeutics initiated with a Hold at SunTrust
SunTrust analyst Peter Larson initiated CRISPR Therapeutics with a Hold and a $16 price target.
07/17/17
OPCO
07/17/17
INITIATION
OPCO
Perform
Crispr Therapeutics initiated with a Perform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started Crispr Therapeutics (CRSP) with a Perform rating saying the company is in a weaker patent position than competitor Editas Medicine (EDIT).
09/06/17
LEHM
09/06/17
INITIATION
LEHM
Overweight
Crispr Therapeutics assumed with an Overweight at Barclays
Barclays assumed Crispr with an Overweight rating and a $29 price target, up from $22, citing substantial upside as "more clinical data are generated from CRSP/NTLA/EDIT to further support broad application of CRISPR/Cas9 technology."
03/28/17
CHDN
03/28/17
INITIATION
Target $23.5
CHDN
Buy
CRISPR Therapeutics initiated with a Buy at Chardan
Chardan analyst Madhu Kumar initiated CRISPR Therapeutics with a Buy and a $23.50 price target saying upside from clinical leadership in CRISPR therapy offsets any potential downside from its IP exposure.
JNCE Jounce Therapeutics
$14.77

0.24 (1.65%)

02/21/17
02/21/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Snap Inc (SNAP) initiated with a Neutral rating and a $14 price target at Atlantic Equities, who said that expansion beyond the core audience is likely challenging, sustainability of engagement concerns will persist, and margins are structurally lower than peers. 2. REV Group (REVG) initiated with an Outperform at Credit Suisse. 3. Nokia (NOK) initiated with a Buy at Craig-Hallum. 4. Freeport McMoRan (FCX) initiated with a Neutral at Citi. 5. Jounce Therapeutics (JNCE) initiated with an Outperform at Cowen, with an Outperform at Wells Fargo and with an Overweight at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/21/17
COWN
02/21/17
INITIATION
COWN
Outperform
Jounce Therapeutics initiated with an Outperform at Cowen
Cowen analyst Boris Peaker started Jounce Therapeutics with an Outperform rating and no price target. The analyst believes JTX-2011 can have clinical utility in a wide range of malignancies and notes the company is well capitalized.
02/21/17
WELS
02/21/17
INITIATION
WELS
Outperform
Jounce Therapeutics initiated with an Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough started Jounce Therapeutics with an Outperform rating and $30-$33 price target range. The analyst cites the company's "industry-leading translational science effort on identifying novel immuno-oncology targets."
02/21/17
JPMS
02/21/17
INITIATION
Target $28
JPMS
Overweight
Jounce Therapeutics initiated with an Overweight at JPMorgan
JPMorgan analyst Cory Kasimov started Jounce Therapeutics with an Overweight rating and $28 price target. The analyst believes current share levels offer an attractive entry for the pure play immuno-oncology company.
NKTR Nektar
$32.50

0.76 (2.39%)

11/09/17
11/09/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AnaptysBio (ANAB) initiated with a Buy at Jefferies. 2. Regenxbio (RGNX) resumed with an Overweight at Morgan Stanley. 3. GTx (GTXI) initiated with a Buy at Stifel. 4. Idera Pharmaceuticals (IDRA) initiated with a Buy at H.C. Wainwright. 5. Nektar (NKTR) initiated with a Buy at Canaccord. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/08/17
JEFF
11/08/17
NO CHANGE
Target $35
JEFF
Buy
Nektar price target raised to $35 from $23 at Jefferies
Jefferies analyst David Steinberg raised his price target for Nektar Therapeutics to $35 saying that while the Q3 results topped expectations, the big news last night is that the company is planning to file a new drug application for NKTR-181 in April 2018 based on the feedback from a recent FDA meeting. This is nearly two years earlier than previously expected, Steinberg tells investors in a post-earnings research note. He reiterates a Buy rating on Nektar.
09/26/17
MZHO
09/26/17
INITIATION
Target $30
MZHO
Buy
Nektar initiated with a Buy at Mizuho
Mizuho analyst Difei Yang initiated Nektar with a Buy and $30 price target.
11/09/17
ADAM
11/09/17
INITIATION
Target $35
ADAM
Buy
Nektar initiated with a Buy at Canaccord
Canaccord Genuity analyst Arlinda Lee started Nektar Therapeutics with a Buy rating and $35 price target. The analyst views the company's immunology and oncology pipeline as attractive.
SNDX Syndax
$10.11

0.09 (0.90%)

05/18/17
JMPS
05/18/17
NO CHANGE
JMPS
Syndax data 'impressive,' says JMP Securities
JMP Securities analyst Michael King says that the objective response rate for the company's entinostat in melanoma patients in a Phase 1b/Phase II trial was "impressive." The analyst remains upbeat on the treatment and keeps an Outperform rating on the stock.
03/24/17
COWN
03/24/17
INITIATION
COWN
Outperform
Syndax initiated with an Outperform at Cowen
Cowen analyst Chris Shibutani initiated Syndax with an Outperform commenting it is poised to succeed in developing entinostat for advanced HR+ breast cancer. Additional upside could be driven by IO combination studies, which capitalize on entinostat's unique mechanism of action, complementary to checkpoint inhibitors.
08/11/17
OPCO
08/11/17
NO CHANGE
Target $29
OPCO
Outperform
Syndax price target raised to $29 from $25 at Oppenheimer
Oppenheimer analyst Hartaj Singh raised his price target for Syndax Pharmaceuticals to $29 saying he remains bullish following the Q2 results and business update. The Encore 601 trial melanoma stage two cohort continues to build on its "impressive" ASCO 2016 data, with full enrollment in Q3, a full quarter ahead of schedule, the analyst tells investors in a research note. He keeps an Outperform rating on Syndax.
05/18/17
SBSH
05/18/17
NO CHANGE
Target $24
SBSH
Buy
Syndax price target raised to $24 from $20 at Citi
Citi analyst Joel Beatty raised his price target for Syndax Pharmaceuticals to $24 saying he's encouraged by the early response data reported yesterday afternoon for Entinostat plus Keytruda in melanoma. The data are compelling enough to increase the drug's probability of approval in melanoma to 30% from 20%, Beatty tells investors in a research note. He keeps a Buy rating on Syndax.
IDRA Idera Pharmaceuticals
$2.11

0.09 (4.46%)

11/09/17
PIPR
11/09/17
NO CHANGE
Target $4
PIPR
Overweight
Piper reiterates Overweight rating on Idera after IMO-2125 trial update
After Idera Pharmaceuticals reported a 5th unconfirmed RECIST response in its ongoing IMO-2125 plus Yervoy combo trial in PD-1 refractory metastatic melanoma, bringing the ORR to 50%, Piper Jaffray analyst Edward Tenthoff reiterated his Overweight rating and $4 price target on the stock, which is up 15% to $2.03 in midday trading.
11/09/17
HCWC
11/09/17
INITIATION
Target $4
HCWC
Buy
Idera Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth started Idera Pharmaceuticals with a Buy rating and $4 price target. The company's two lead products have "significant potential in the fast growing immunotherapy market," the analyst contends.
04/25/17
04/25/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sony (SNE) initiated with an Outperform at Bernstein. 2. Rockwell Collins (COL) reinstated with a Sell at Goldman Sachs. 3. Idera Pharmaceuticals (IDRA) initiated with an Outperform at Baird. 4. GasLog (GLOG) initiated with an Outperform at Credit Suisse. 5. Fitbit (FIT) initiated with a Buy at Benchmark. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
FPRX Five Prime
$28.83

1.06 (3.82%)

11/07/17
SBSH
11/07/17
NO CHANGE
Target $65
SBSH
Buy
Citi says data puts safety of Five Prime's cabiralizumab in question
The key point of today's abstract was 43% G3-5 toxicity related to Five Prime Therapeutics' cabiralizumab, which puts the safety of the drug in question, Citi analyst Robyn Karnauskas tells investors in a research note. The analyst, who notes the data do show some durable activity, does not know at what dose the safety issues occurred. It remains unclear at this point if the activity being seen is due to checkpoint or cabiralizumab's contribution, Karnauskas writes. She models a 35% probability to the cabiralizumab program, which contributes $34 to her price target of $65. The analyst has a Buy rating on Five Prime. The stock is down 34% to $28.67.
11/07/17
NOMU
11/07/17
NO CHANGE
Target $94
NOMU
Buy
Five Prime selloff today 'unfounded,' says Nomura Instinet
Nomura Instinet analyst Christopher Marai views the selloff today in shares of Five Prime Therapeutics as "unfounded." The disease control rate of 13% observed with some patients out to 293 days is "impressive," Marai tells investors in a research note. Five Prime today presented data from the Phase 1a/1b clinical trial evaluating the immunotherapy combination of its CSF-1R antibody, cabiralizumab, with Bristol-Myers' Opdivo, in pancreatic cancer patients. The analyst reminds investors that cabiralizumab is also mechanistically more likely to provide benefit to pancreatic patients in earlier stages of progressing to metastatic disease or immediately following first line treatment. He believes today's data establishes efficacy and keeps a Buy rating on Five Prime with a $94 price target. The stock is off the day's lows but remains down 37%, or $16.20, to $27.56
11/07/17
JEFF
11/07/17
NO CHANGE
Target $52
JEFF
Buy
Five Prime data not as strong as expected, says Jefferies
Jefferies analyst Eun Yang says the 10% overall response rate with Five Prime Therapeutics' cabiralizumab plus Opdivo in second-line pancreatic cancer is lower than expected and the six-month disease control rate of 13%. The data are "not as strong as we like to see," but compares reasonably to chemo combo in second-line pancreatic cancer, Yang tells investors in a research note. The analyst has a Buy rating on Five Prime Therapeutics with a $52 price target. The stock in midday trading is down 34% to $28.69.
NVS Novartis
$82.38

-0.1 (-0.12%)

10/31/17
LEER
10/31/17
NO CHANGE
Target $37
LEER
Outperform
Intellia Therapeutics price target raised to $37 from $29 at Leerink
Leerink analyst Joseph Schwartz said Intellia Therapeutics' (NTLA) demonstration of gene editing across multiple animal models brings the company one-step closer to an IND filing. He also believes investors are pricing in an M&A premium following Gilead's (GILD) acquisition of Kite and the approvals of Novartis' (NVS) Kymriah and Gilead's Yescarta. Noting that his valuation "now incorporates a very small fraction" of the Kite acquisition value, he raised his price target on Intellia to $37 from $29 and keeps an Outperform rating on the shares.
10/30/17
JMPS
10/30/17
DOWNGRADE
JMPS
Market Perform
Advanced Accelerator downgraded to Market Perform at JMP Securities
JMP Securities analyst Michael King downgraded Advanced Accelerator (AAAP) to Market Perform from Outperform saying a competing takeover bid to Novartis' (NVS) is unlikely.
10/25/17
LEHM
10/25/17
DOWNGRADE
LEHM
Underweight
Novartis downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Emmanuel Papadakis downgraded Novartis to Underweight and cut his price target for the shares to CHF 75 from CHF 80. Following the Q3 results, the analyst believes Entresto estimates remain too high and that competitive pressure increasing for Cosentyx. He sees a lack of catalysts in the near-term beyond RTH258.
10/20/17
10/20/17
DOWNGRADE
Target $0.9

Hold
Durect downgraded to Hold on 'major disappointment' of Posimir failure at Stifel
As previously reported, Stifel analyst Adam Walsh downgraded Durect (DRRX) to Hold from Buy, calling the fact that the company's Phase 3 Posimir trial in post-surgical pain did not meet its primary efficacy endpoint a "major disappointment." He has removed all Posimir revenue from his model and expects Novartis' (NVS) Sandoz will end the Posimir partnership. Walsh lowered his price target to 90c from $3.00 on Durect shares, which are down 55% to 87c in pre-market trading.
OMED OncoMed
$4.87

0.14 (2.96%)

04/17/17
RHCO
04/17/17
DOWNGRADE
RHCO
Hold
OncoMed downgraded to Hold from Buy at SunTrust
07/10/17
PIPR
07/10/17
NO CHANGE
Target $5
PIPR
Neutral
OncoMed termination from GSK not surprising, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff believes GlaxoSmithKline (GSK) terminating its agreement with OncoMed Pharmaceuticals (OMED) is not surprising since tarextumab, the only remaining asset under the collaboration, failed previously to meet the primary endpoint in a Phase II study for first-line small cell lung cancer. The analyst says he remains focused on OncoMed's early stage pipeline including navicixizumab, rosmantuzumab and I/O assets anti-TIGIT and GITR trimer. Tenthoff keeps a Neutral rating on OncoMed with a $5 price target.
04/17/17
JMPS
04/17/17
DOWNGRADE
JMPS
Market Perform
OncoMed downgraded to Market Perform from Outperform at JMP Securities
04/17/17
PIPR
04/17/17
DOWNGRADE
Target $5
PIPR
Neutral
Piper downgrades OncoMed after second failed study
Piper Jaffray analyst Edward Tenthoff downgraded OncoMed Pharmaceuticals to Neutral from Overweight after the company's Phase II tarextumab study in first-line small cell lung cancer failed. The analyst cut his price target for the shares to $5 from $17. The trial failure follows last week's negative Phase II data on demcizumab in first-line pancreatic cancer last week, Tenthoff tells investors in a research note. OncoMed in morning trading is down 20% to $3.86.
DNA Bought by RHHBY

10/13/17
KEYB
10/13/17
NO CHANGE
Target $106
KEYB
Overweight
Auto suppliers supported by stronger Euro and rising EU output, says KeyBanc
KeyBanc analyst Brett Hoselton raised his profit targets on several auto suppliers, maintaining a positive view on the group overall heading into Q3 earnings. Hoselton says the outlook for the quarter is intact, as lower than expected production of light vehicles was in part offset by stronger EU output. He also cites FX tailwinds, with the Euro have appreciated about 7% sequentially and further supporting revenue in Q3 and possibly FY18. Hoselton raised his profit targets on Delphi Automotive (DLPH) to $106 from $100, Magna International (MGA) to $59 from $55, Lear Corp (LEA) to $184 from $180, and BorgWarner (BWA) to $56 from $50, maintaining an Overweight rating on all these stocks. The analyst is especially bullish on Dana Inc (DNA) given the recent upward revisions to North America Class 8 production, but says his Sector Weight rating reflects the stock prices.
BAYRY Bayer
$32.05

-0.211 (-0.65%)

10/03/17
RHCO
10/03/17
NO CHANGE
RHCO
TG Therapeutics has positive read through from Bayer approval, says SunTrust
SunTrust analyst Yatin Suneja believes that the FDA's decision to grant accelerated approval to Bayer's (BAYRY) Aliqopa, a PI3K-delta inhibitor, as a treatment for Relapsed/Refractory Follicular Lymphoma, bodes well for TG Therapeutics' (TGTX) own PI3K-delta inhibitor, TGR-120. The analyst says that the lack of a black box warning on Bayer's Aliqopa shows that not all PI3K-delta inhibitors have the safety issues that have been attributed to them in the past. Suneja says that "Aliqopa's approval reflects positively on TGR-1202, which offers best-in-class safety , and provides clarity on TGR-1202's regulatory pathway in" lymphoma The analyst says that investors are "overlooking" its potential in " lymphoma, and keeps a Buy rating on the shares.
10/16/17
JEFF
10/16/17
NO CHANGE
Target $115
JEFF
Buy
Jefferies ups price target on top global pick AbbVie to $115
Jefferies analyst Jeffrey Holford keeps AbbVie (ABBV) as his top global Pharmaceuticals pick for October, followed by Roche (RHHBY), Novartis (NVS), Bayer (BAYRY), Johnson & Johnson (JNJ), Eli Lilly (LLY) and GlaxoSmithKline (GSK). The analyst raised his price target for AbbVie shares to $115 from $107 and keeps a Buy rating on the name. Among his other target changes include bumping Eli Lilly's to $100 from $96.
10/16/17
RHCO
10/16/17
NO CHANGE
Target $35
RHCO
Buy
Cabo result better positions Exelixis as acquisition target, says SunTrust
SunTrust analyst Peter Lawson raised his price target on Exelixis (EXEL) to $35 from $33 and maintained his Buy rating, saying the latest CELESTIAL trial cabozantinib positions the treatment well against its main competitor - Bayer's (BAYRY) Regorafenib. Lawson adds that the trial result validates the expansion of cabozantinib beyond kidney cancer and better positions Exelixis as a potentially attractive M&A target.
10/17/17
NEED
10/17/17
NO CHANGE
Target $33
NEED
Buy
Exelixis price target raised to $33 from $30 at Needham
Needham analyst Chad Messer raised his price target on Exelixis (EXEL) to $33, noting the latest trial data for advanced renal cell carcinoma treatment, Cabozantinib, positions it for near and long term growth. Messer says the results may be sufficient to allay competitive concerns from the recently approved Bayer (BAYRY) Stivarga, as cabozantinib offers a potentially more attractive efficacy profile.
AZN AstraZeneca
$32.91

-0.2 (-0.60%)

09/22/17
09/22/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. American Airlines (AAL) upgraded to Overweight from Equal Weight at Barclays with analyst Brandon Oglenski saying the company appears to have all the attributes of a "value compounding opportunity" for equity investors. 2. Mindbody (MB) upgraded to Overweight from Sector Weight at KeyBanc with analyst Brent Bracelin saying elevated churn risk from the company's model transition to higher-value subscribers is now discounted into the valuation. 3. Enviva (EVA) upgraded to Buy from Neutral at Citi with analyst Ryan Levine saying he likes the risk/reward at current levels and believes Enviva is well positioned in the next 12-18 months. 4. PSEG (PEG) upgraded to Overweight from Equal Weight at Barclays with analyst Gregg Orrill saying the company could be the industry's largest beneficiary of potential near-term policy initiatives. 5. AstraZeneca (AZN) upgraded to Outperform from Market Perform at Bernstein with analyst Tim Anderson saying that the outlook of its current products has improved, leaving it well-positioned to grow even if its pipeline does not yield any new drugs through 2025. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/16/17
FBCO
10/16/17
UPGRADE
FBCO
Outperform
AstraZeneca upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Rebekah Harper upgraded AstraZeneca to Outperform from Neutral saying that after recent pipeline success for Tagrisso and Imfinzi, she sees a marked improvement in its strategic position in pricing power and replacement power.
10/16/17
10/16/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Apple (AAPL) was upgraded to Overweight from Sector Weight at KeyBanc and Pacific Crest. 2. Infinera (INFN) upgraded to Neutral from Sell at Citi with analyst Stanley Kovler saying the risk/reward is balanced with material downward revisions to estimates likely limited. 3. AstraZeneca (AZN) upgraded to Outperform from Neutral at Credit Suisse with analyst Rebekah Harper saying that after recent pipeline success for Tagrisso and Imfinzi, she sees a marked improvement in its strategic position in pricing power and replacement power. 4. KKR (KKR) upgraded to Buy from Neutral at Goldman Sachs with analyst Alexander Blostein citing a more stable, improving mix of balance sheet investments, lower concentration in large public holdings, and increased mix towards private holdings. 5. Groupon (GRPN) upgraded to Market Perform from Underperform at Cowen with analyst Thomas Champion saying he believes the shares currently look more attractive given the company's new management and cost controls, improved North America results, and balanced expectations for the second half of 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/25/17
RHCO
09/25/17
NO CHANGE
Target $19
RHCO
Buy
NewLink collaboration with AstraZeneca a validation, says SunTrust
SunTrust analyst Peter Lawson said NewLink Genetics' (NLNK) newly-announced collaboration with AstraZeneca (AZN) is the first "big pharma" partnership for NewLink's lead IDO pathway inhibitor. The deal adds external validation to an asset that is "trading at a fraction" of Incyte's IDO, said Lawson, who keeps a Buy rating and $19 price target on NewLink shares.
ARRY Array BioPharma
$11.00

0.18 (1.66%)

09/11/17
JPMS
09/11/17
NO CHANGE
Target $14
JPMS
Overweight
Array BioPharma price target raised to $14 from $11 at JPMorgan
JPMorgan analyst Anupam Rama raised his price target for Array BioPharma to $14 following ESMO presentations for the company. Key presentations for Array at the conference include Columbus Part 2 results of binimetinib/encorafenib in BRAF melanoma and binimetinib/encorafenib/cetuximab Beacon results in BRAF colorectal cancer, Rama tells investors in a research note. The focus at ESMO was on Beacon colorectal cancer and the 41% overall response rate observed in the safety lead-in period "meaningfully beat expectations," the analyst writes. He believes Array shares should have rallied more than 7% on Friday. Rama reiterates an Overweight rating on the name.
09/11/17
CANT
09/11/17
NO CHANGE
Target $15
CANT
Overweight
Array BioPharma price target raised to $15 from $13 at Cantor
Cantor Fitzgerald analyst Mara Goldstein raised her price target for Array BioPharma to $15 saying the safety lead-in data from the Beacon study show "encouraging signs" of the potential to widen the market potential for binimetinib and encorafenib. These data "lend additional support" for the drugs as best-in-class for the treatment of advanced melanoma, Goldstein tells investors in a research note.The analyst has an Overweight rating on Array shares.
09/20/17
PIPR
09/20/17
NO CHANGE
Target $18
PIPR
Overweight
Array BioPharma price target raised to $18 from $14 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Array BioPharma to $18 and reiterates an Overweight rating on the shares. The company recently strengthened its balance sheet ahead of next summer's approvals, Tenthoff tells investors in a research note. The FDA accepted new drug applications for binimetinib and encorafenib for BRAF-mutant melanoma and the analyst anticipates approval by the June 30 action date.
09/08/17
PIPR
09/08/17
NO CHANGE
Target $14
PIPR
Overweight
Piper reiterates Overweight on Array after 'encouraging' data
Piper Jaffray analyst Edward Tenthoff says Array BioPharma and Pierre Fabre reported "encouraging" Phase III trial results in 30 BRAF-mutant colorectal cancer patients receiving binimetinib, encorafenib and cetuximab. The analyst expects approval of binimetinib and encorafenib in BRAF-mutant melanoma next year. He reiterates an Overweight rating on Array with a $14 price target.
TSRO Tesaro
$91.09

0.08 (0.09%)

11/09/17
LSCM
11/09/17
NO CHANGE
Target $143
LSCM
Buy
Tesaro price target lowered to $143 from $202 at Lake Street
Lake Street analyst Bruce Jackson cut his price target for Tesaro shares to $143 saying management guided cautiously for 2017. The analyst reduced his revenue estimates to reflect revised assumptions for Zejula in the U.S. and a slower ramp in Europe plus tempered expectations for Varubi/Varuby. The analyst maintains a Buy rating on the shares.
10/23/17
PIPR
10/23/17
DOWNGRADE
Target $117
PIPR
Neutral
Tesaro assumed with a Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond downgraded Tesaro to Neutral after assuming coverage of the name. The analyst sees "decreasing differentiation" in the PARP space and believes a takeout at a significant premium, while possible, is not as probable as bulls contend. He finds it "difficult to find upside from current valuations" in the absence of a takeover and cut his price target for the shares to $117 from $180.
10/23/17
LEHM
10/23/17
INITIATION
Target $135
LEHM
Equal Weight
Tesaro initiated with an Equal Weight at Barclays
Barclays analyst Paul Choi started Tesaro (TSRO) with an Equal Weight rating and $135 price target. While near-term consensus sales estimates are beatable, growing PARP competition will challenge Zejula over the long term, Choi tells investors in a research note. The analyst this morning also initiated Clovis Oncology (CLVS) with an Overweight rating.
11/08/17
MSCO
11/08/17
NO CHANGE
Target $165
MSCO
Overweight
Tesaro price target lowered to $165 from $181 at Morgan Stanley
Morgan Stanley analyst Andrew Berens noted that Tesaro's 2017 guidance, which implies Zejula quarter-over-quarter growth of flat to 25%, represents an expected sequential growth slowdown in Q4 that may disappoint some investors. The analyst, who lowered his sales estimates for Zejula following the Q3 report and guidance update, cut his price target on Tesaro shares to $165 from $181, but he maintains an Overweight rating on the shares.
XNCR Xencor
$21.03

1.07 (5.36%)

12/08/16
LEER
12/08/16
NO CHANGE
Target $35
LEER
Outperform
Xencor price target raised to $35 from $30 at Leerink
Leerink analyst Michael Schmidt raised his price target for Xencor to $35 from $30 following its recent $127M equity financing, which should enable the company to accelerate and broaden development of its bispecific antibody pipeline as well as support potential pivotal trials of lead product XmAb5871 in IgG4-related disease. The analyst remains positive on Xencor's outlook as he believes the company's differentiated antibody engineering platform will continue to garner strategic interest while existing partnered and proprietary pipeline programs mature, providing upside to the current valuation. He reiterates an Outperform rating on the shares.
03/01/17
NOMU
03/01/17
INITIATION
Target $21
NOMU
Neutral
Xencor initiated with a Neutral at Nomura
Nomura initiated Xencor with a Neutral and a $21 price target.
11/28/16
ADAM
11/28/16
NO CHANGE
Target $32
ADAM
Buy
Xencor price target raised to $32 from $27 at Canaccord
Canaccord analyst Arlinda Lee raised her price target on Xencor to $32 from $27 citing its XmAb pipeline and attractive bispecifics capabilities and the company's mechanistic rationale for treating IgG4-RD with XmAb5871. Lee reiterated her Buy rating on Xencor shares.

TODAY'S FREE FLY STORIES

DE

Deere

$139.23

2.31 (1.69%)

20:25
11/21/17
11/21
20:25
11/21/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 28

    Nov

PCRX

Pacira

$42.65

0.45 (1.07%)

19:24
11/21/17
11/21
19:24
11/21/17
19:24
Recommendations
Pacira analyst commentary at BMO Capital »

October Symphony data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 14

    Dec

  • 06

    Apr

CEIX

CONSOL Energy

, ICON

Iconix Brand

$2.55

0.28 (12.33%)

19:00
11/21/17
11/21
19:00
11/21/17
19:00
Hot Stocks
S&P announces changes to S&P SmallCap 600 index »

S&P Dow Jones Indices…

CEIX

CONSOL Energy

ICON

Iconix Brand

$2.55

0.28 (12.33%)

CNX

Consol

$16.27

0.23 (1.43%)

PDFS

PDF Solutions

$15.86

0.11 (0.70%)

BBOX

Black Box

$4.15

0.55 (15.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIVO

TiVo

$17.65

0.15 (0.86%)

, CMCSA

Comcast

$36.42

0.59 (1.65%)

18:52
11/21/17
11/21
18:52
11/21/17
18:52
Recommendations
TiVo, Comcast analyst commentary at JPMorgan »

ITC ruling a…

TIVO

TiVo

$17.65

0.15 (0.86%)

CMCSA

Comcast

$36.42

0.59 (1.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GKOS

Glaukos

$25.35

-2.86 (-10.14%)

18:48
11/21/17
11/21
18:48
11/21/17
18:48
Recommendations
Glaukos analyst commentary at Piper Jaffray »

Glaukos selloff due to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$103.00

0.25 (0.24%)

, CMCSA

Comcast

$36.42

0.59 (1.65%)

18:31
11/21/17
11/21
18:31
11/21/17
18:31
Periodicals
Hulu sued for failure to offer audio service for blind subscribers, NY Post says »

Advocacy groups are suing…

DIS

Disney

$103.00

0.25 (0.24%)

CMCSA

Comcast

$36.42

0.59 (1.65%)

CMCSK

Comcast

TWX

Time Warner

$89.56

1.85 (2.11%)

FOX

21st Century Fox

$30.10

0.2 (0.67%)

FOXA

21st Century Fox

$30.88

0.22 (0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGA

Magna

$54.29

0.37 (0.69%)

18:23
11/21/17
11/21
18:23
11/21/17
18:23
Hot Stocks
Magna announces two share repurchase programs »

Magna International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 16

    Jan

PTLA

Portola Pharmaceuticals

$50.80

1.29 (2.61%)

18:23
11/21/17
11/21
18:23
11/21/17
18:23
Hot Stocks
Portola: FDA extends review period for PAS for Bevyxxa »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

PBMD

Prima BioMed

$1.65

-0.03 (-1.79%)

18:09
11/21/17
11/21
18:09
11/21/17
18:09
Hot Stocks
Prima BioMed secures European patent grant for lead product IMP321 in cancer »

Prima BioMed announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRT

Copart

$36.70

0.39 (1.07%)

18:06
11/21/17
11/21
18:06
11/21/17
18:06
Earnings
Copart reports Q1 non-GAAP EPS 33c, consensus 27c »

Reports Q1 revenue 419.2M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 19

    Dec

PCTY

Paylocity

$47.79

-0.64 (-1.32%)

18:01
11/21/17
11/21
18:01
11/21/17
18:01
Hot Stocks
Paylocity chairman sells 736,845 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

MDC

M.D.C. Holdings

$35.10

0.91 (2.66%)

18:01
11/21/17
11/21
18:01
11/21/17
18:01
Hot Stocks
M.D.C. Holdings declares special 8% stock dividend »

M.D.C. Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDFS

PDF Solutions

$15.86

0.11 (0.70%)

, BBOX

Black Box

$4.15

0.55 (15.28%)

17:59
11/21/17
11/21
17:59
11/21/17
17:59
Hot Stocks
Breaking Hot Stocks news story on PDF Solutions, Black Box »

PDF Solutions to replace…

PDFS

PDF Solutions

$15.86

0.11 (0.70%)

BBOX

Black Box

$4.15

0.55 (15.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$22.46

0.34 (1.54%)

17:58
11/21/17
11/21
17:58
11/21/17
17:58
Hot Stocks
Breaking Hot Stocks news story on HP Inc. »

HP Inc. sees pressure on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CEIX

CONSOL Energy

, ICON

Iconix Brand

$2.55

0.28 (12.33%)

17:57
11/21/17
11/21
17:57
11/21/17
17:57
Hot Stocks
Breaking Hot Stocks news story on CONSOL Energy, Iconix Brand »

CONSOL Energy to replace…

CEIX

CONSOL Energy

ICON

Iconix Brand

$2.55

0.28 (12.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$22.46

0.34 (1.54%)

17:53
11/21/17
11/21
17:53
11/21/17
17:53
Hot Stocks
Breaking Hot Stocks news story on HP Inc. »

HP Inc. says returned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

TMQ

Trilogy Metals

$0.92

-0.0211 (-2.25%)

17:53
11/21/17
11/21
17:53
11/21/17
17:53
Syndicate
Breaking Syndicate news story on Trilogy Metals »

Trilogy Metals files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRNO

Terreno Realty

$37.74

0.74 (2.00%)

17:50
11/21/17
11/21
17:50
11/21/17
17:50
Initiation
Terreno Realty initiated at National Securities »

Terreno Realty initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

HPQ

HP Inc.

$22.47

0.355 (1.61%)

17:47
11/21/17
11/21
17:47
11/21/17
17:47
Hot Stocks
HP Inc.: 'Stay tuned' for news on metal 3D printing »

Says plans to introduce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

THC

Tenet

$13.34

0.17 (1.29%)

17:47
11/21/17
11/21
17:47
11/21/17
17:47
Initiation
Tenet initiated at William Blair »

Tenet initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPNT

LifePoint

$43.85

0.65 (1.50%)

17:47
11/21/17
11/21
17:47
11/21/17
17:47
Initiation
LifePoint initiated at William Blair »

LifePoint initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LHCG

LHC Group

$67.98

1.46 (2.19%)

17:46
11/21/17
11/21
17:46
11/21/17
17:46
Initiation
LHC Group initiated at William Blair »

LHC Group initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

HLS

HealthSouth

$48.46

0.85 (1.79%)

17:46
11/21/17
11/21
17:46
11/21/17
17:46
Initiation
HealthSouth initiated at William Blair »

HealthSouth initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCA

HCA Healthcare

$75.89

1.28 (1.72%)

17:46
11/21/17
11/21
17:46
11/21/17
17:46
Initiation
HCA Healthcare initiated at William Blair »

HCA Healthcare initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

AMED

Amedisys

$54.97

2.29 (4.35%)

17:45
11/21/17
11/21
17:45
11/21/17
17:45
Initiation
Amedisys initiated at William Blair »

Amedisys initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.